Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that androgen deprivation therapy in prostate cancer patients was associated with fewer SARS-CoV-2 infections but did not reduce COVID-19 disease severity or hospitalizations.

Androgen deprivation therapy might help prevent severe COVID-19, but more research is needed.

This review discusses the link between androgen receptor action and TMPRSS2 expression in severe COVID-19, exploring the potential of anti-androgens to mitigate disease severity in men and notes ongoing trials.

This review suggests that understanding the biological and molecular reasons for more severe COVID-19 in men, particularly those at risk for prostate cancer, could improve management of these patients, but reports no new results.

This review discusses the dual role of testosterone in COVID-19 progression and suggests its importance in understanding the disease's mechanisms, highlighting the need for further targeted research.

This study found that androgen deprivation therapy is associated with an increased risk of acquired long-QT syndrome and Torsades de Pointes, particularly highlighting enzalutamide's greater association with sudden death compared to other therapies.

This article reviews the possible therapeutic activities of Angelica gigas Nakai root extracts and their components, noting their potential effects on neuro-cognitive, metabolic, and other health conditions, and reports no new clinical results.

This study found that men receiving enzalutamide and other androgen-deprivation therapies may be at increased risk for QT prolongation and torsades de pointes.

New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.

The authors reviewed the mechanisms behind Kennedy's disease, noting advances in therapeutic strategies such as androgen deprivation and gene silencing that may soon expand treatment options for this incurable neuromuscular condition.

This review highlights recent insights into using antiandrogens as preventive and therapeutic measures against COVID-19, emphasizing their role in blocking viral infection by modulating androgen-mediated host protease TMPRSS2 and cell entry protein ACE2, with varying success in clinical trials.

This review describes the shift in treating symptomatic benign prostatic hyperplasia from surgery to 5alpha-reductase inhibitor drugs, which may provide symptom relief and alter BPH's progression, but reports no new clinical results.

This article summarizes various studies in adult urology, including those on diagnostic techniques for prostate cancer and outcomes of different treatments for benign prostatic hyperplasia, but reports no new findings.

Dutasteride may help treat prostate cancer by causing cancer cells to shrink and die.

This review highlights recent advancements in prostate cancer treatments, particularly new drugs targeting signaling pathways and showing promise in clinical trials, but notes the high recurrence rate of castration-resistant cancer post-therapy, requiring ongoing efforts for effective solutions.

This paper discusses the variability in COVID-19 susceptibility and severity, emphasizing factors like biological differences and suggesting potential precision medicine approaches, but it reports no new clinical results.

This study found that castration-resistant prostate cancers resistant to CYP17A1 inhibitors may still depend on steroids and could respond to therapies targeting de novo intratumoral steroid synthesis.

This systematic review found that antiandrogens do not appear to protect against SARS-CoV-2 infection or reduce COVID-19 severity, suggesting their use is not advisable for COVID-19 treatment.

This review discusses the roles of sex hormones in COVID-19 progression and highlights conflicting evidence on their protective effects and the complexity of sex and gender influences on the disease.

This paper proposes a novel theory that certain symptoms of Post-Finasteride Syndrome may be caused by an overgrowth of hydrogen sulphide-producing bacteria in the small intestine, which acts as a mitochondrial toxin, with implications for treatment targeting the gut microbiome.

This theoretical paper proposes that a subset of Post-Finasteride Syndrome cases may be driven by a gut-derived toxic process involving hydrogen sulphide-producing bacteria, suggesting that the small intestinal microbiome could be a potential target for treating this condition.

The researchers suggest that testosterone levels might influence COVID-19 susceptibility and severity, with low levels potentially protecting against infection but possibly worsening severe disease due to cytokine storm activation.

This review examines existing research on androgen deprivation therapy and its effects on male sex hormones in relation to COVID-19, but reports no new clinical findings.

In this study, finasteride doubled the duration of the first off-cycle in intermittent androgen deprivation therapy for mice with LNCaP tumors but did not improve overall survival.

This review discusses the role of the androgen receptor in breast cancer diagnosis and treatment, and notes a lack of new research results on its therapeutic potential.

The Androgen Receptor could be a target for treating diseases like cancer, but more research is needed to confirm the effectiveness of potential treatments.

This review discusses evidence on androgen sensitivity as a potential factor in COVID-19 disease severity, suggesting that androgen receptor interactions could influence virus entry and progression, and reports no new clinical results.

This study found that the active use of androgen deprivation therapy was not associated with a reduced risk of death in prostate cancer patients with COVID-19.

This paper reviews the role of androgens in SARS-CoV-2 infection and their potential impact on disease severity, suggesting androgen-targeting strategies might influence outcomes, but reports no new clinical results.

In this study, researchers examined androgen receptor activity in the adult mouse brain and found specific expression in key brain areas, which could inform understanding of cognitive side effects in humans undergoing androgen deprivation therapy for prostate cancer.